British Journal of Clinical Pharmacology, EarlyView.Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
Early Enrollment in Diabetes Pay-for-Performance Program Reduced Loss of Life Expectancy in Newly-Diagnosed Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2025;49:1051-63). [PDF]
Diabetes Metab JQazi F, Qazi S.
europepmc +1 more source
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
British Journal of Clinical Pharmacology, EarlyView.Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Impacts and lessons learned from coronavirus-19 pandemic in the United States: preparing for future public health emergencies. [PDF]
Health Econ RevXu O.
europepmc +1 more source
British Journal of Clinical Pharmacology, EarlyView.Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić +4 more
wiley +1 more source
Population health management in Saudi Arabia: A narrative review of system undergoing reform. [PDF]
Dialogues HealthAlkhurayji K +3 more
europepmc +1 more source
Textual quantitative analysis of China's fertility-friendly policies--based on a two dimensional analytical framework of policy tools and policy objectives. [PDF]
BMC Public HealthKang Y +8 more
europepmc +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
The management of nurses in internet-based home care in tertiary general hospitals in China: a mixed methods study. [PDF]
BMC NursCao Z, Yue L, Peng H, Li B, Peng B.
europepmc +1 more source
The Determinants of Non-life Insurance Market Demand in China
, 2006 Zhao GuiQin
openalex +1 more source